Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Abroad (travel likely)RecruitingPHASE2
Conditions
Non Squamous Non Small Cell Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Korea University Anam Hospital, Anam, South Korea
Contact: Study coordinator (Sooin Choi, M.D.)Hallym University Sacred Heart Hospital, Anyang, South Korea
Contact: Study coordinator (Seung Hoon Jang)Chonnam National University Hwasun Hospital, Hwasun, South Korea
Contact: Study coordinator (Injae Oh, M.D.)Catholic University of Korea EunPyeong St. Mary's Hospital, Seoul, South Korea
Contact: Study coordinator (Chang Dong Yeo, M.D.)Catholic University of Korea Yeouido St. Mary's Hospital, Seoul, South Korea
Contact: Study coordinator (Chan Kwon Park, M.D.)Korea University Guro Hospital, Seoul, South Korea
Contact: Study coordinator (Sung Yong Lee, M.D.)Seoul Asan Hospital, Seoul, South Korea
Contact: Study coordinator (Chang Min Choi, M.D.)Busan National University Hospital Yangsan, Yangsan, South Korea
Contact: Study coordinator (Sunghoon Yoon, M.D.)
Study leads
Sung Yong Lee, MD
Principal Investigator
Korea University Guro Hospital